Winhealth Pharma and TWiB Enter into Strategic Licensing Partnership on AC 203

Winhealth Pharma and TWiB Enter into Strategic Licensing Partnership on AC-203

Condividi: 07 gennaio 2021 SHANGHAI and TAIPEI, Jan. 7, 2021 /PRNewswire/ — Hongkong Winhealth Pharma Group (Winhealth Pharma) and Taiwan TWi Biotechnology, Inc. (TWiB) announced strategic partnership granting Winhealth Pharma exclusive right to develop and commercialize rare disease asset AC-203 in mainland China, Hong Kong and Macao for indications including hereditary epidermolysis bullosa (EB), bullous pemphigoid and other skin diseases.
The prevalence of EB in the United States is aboleggi di più…

WinHealth and Immedica enter agreement giving Winhealth rights to Ravicti® in China and several other Asia Pacific countries

WinHealth and Immedica enter agreement giving Winhealth rights to Ravicti® in China and several other Asia-Pacific countries

Condividi: 31 dicembre 2020 STOCKHOLM and HANGZHOU, China, Dec. 31, 2020 /PRNewswire/ — Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti® (glycerol phenylbutyrate), in a territory covering the Greater China Area, South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand.
Ravicti® is in Europe and North America indicated for treatmeleggi di più…